Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

WideCells Group says 2017 financial statements nearing completion

The additional time required to finalise the results mean its live bookbuild via the Teathers mobile app has been extended until the figures are released
WideCells Group says 2017 financial statements nearing completion
The company said it will update the market in due course

WideCells Group PLC (LON:WDC), the stem cell services and stem cell-related insurance specialist, said its 2017 financial statements are nearing completion.

The additional time required to finalise the results mean its live bookbuild via the Teathers mobile app has been extended until the figures are released.  

READ: WideCells unveils fund-raising details

 In the same market update, Widecells said it is in discussions with the Financial Conduct Authority to lift the share suspension once its numbers have been filed.  

"The company will update the market in due course," it added.

 

View full WDC profile View Profile

WideCells Group Timeline

Related Articles

picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
laboratory
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible
myLotus kit
August 06 2018
The expansion drive is targeting an estimated 2.3mln women per year in the areas of Hebei, Shanghai, Beijing, Shangdong, Henan and Liaoning

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use